Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + tislelizumab + capecitabine + radiotherapy
- Development stage
- Unknown
- Lead developer
- Affiliated Cancer Hospital of Shantou University Medical College
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Liposomal irinotecan + tislelizumab + capecitabine + radiotherapy is an investigational neoadjuvant combination regimen currently in Phase 2 clinical development (NCT07104604) for the treatment of proficient mismatch repair (pMMR) locally advanced mid-lower rectal adenocarcinoma. This multi-modal approach combines the immune checkpoint inhibitor tislelizumab (an anti-PD-1 monoclonal antibody) with the cytotoxic agents liposomal irinotecan (a nanoliposomal topoisomerase I inhibitor) and capecitabine (an oral fluoropyrimidine prodrug), alongside radiotherapy. The regimen is designed to overcome the relative resistance of pMMR rectal cancers to standard immunotherapy by leveraging the synergistic effects of chemotherapy and radiation to enhance tumor immunogenicity and local control. The trial is sponsored by the Affiliated Cancer Hospital of Shantou University Medical College.
- Other names
- neoadjuvant radiotherapy combined with tislelizumab, liposomal irinotecan, and capecitabinenal-IRI + tislelizumab + capecitabine + RT
02
Targets
TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on liposomal irinotecan + tislelizumab + capecitabine + radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + tislelizumab + capecitabine + radiotherapy.